Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals is an Israeli biopharmaceutical company focused on therapeutic development for liver diseases. The company's primary asset is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate in Phase III clinical trials for non-alcoholic steatohepatitis (NASH) treatment in overweight or obese patients with prediabetes or type II diabetes. Galmed is also evaluating Aramchol in the ARRIVE Study, a Phase IIa trial examining its use in HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company's pipeline includes Amilo-5MER, a synthetic pentapeptide in development, and MyBiotics, a pre-clinical asset targeting NASH and fibrosis.

The company maintains a licensing agreement with Samil Pharma for Aramchol commercialization rights in South Korea, and collaborates with OnKai on artificial intelligence platform integration. Galmed operates with a small workforce of three full-time employees and is headquartered in Ramat Gan, Israel. The company was incorporated in 2000 and is listed on the Nasdaq exchange, operating primarily as a development-stage entity with minimal commercial revenue generation to date.